Accueil > Actualité > Société

J&J: stop the study evaluating macitentan 75 mg

( - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its decision to stop the Phase 3 MACiTEPH study evaluating macitentan 75 mg in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) due to futility.

The decision to stop the trial was made in accordance with a recommendation by the study's independent data monitoring committee following a pre-planned interim analysis. No new safety signals were observed.

The interim results of MACiTEPH do not impact any of the Company's commercialized pulmonary hypertension medicines. Additionally, the pivotal Phase 3 UNISUS study, which aims to establish the superiority of a 75 mg dose of macitentan over the currently available 10 mg dose in patients with pulmonary arterial hypertension, is currently continuing as planned.

Copyright (c) 2023 All rights reserved.





A quel niveau sera le CAC40 à fin décembre 2023:

En hausse à 7650Pts
En hausse à 7480Pts
Stable sur le niveau des 7230Pts
En baisse à 7100Pts
En baisse à 6850Pts
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.